Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial

NCT ID NCT07020117

Recruiting now Disease control Sponsor: Aktis Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, breast, lung, cervical, colorectal, or head and neck cancers that have not responded to prior treatments will receive the drug. The main goals are to find the safest dose and to see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[225Ac]Ac-AKY-1189 (a radioactive drug that targets Nectin-4 on cancer cells)
What this could lead to
If successful, this could lead to a new targeted radiation treatment for several types of advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1b) and small study, so safety and effectiveness are not yet known. The radioactive drug may cause side effects, and it may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma cervical adenocarcinoma colorectal adenocarcinoma head and neck cancer Head and Neck Neoplasms hormone receptor-positive breast cancer non-small cell lung carcinoma triple-negative breast carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL ADENOCARCINOMA COLORECTAL ADENOCARCINOMA HEAD AND NECK CANCER HORMONE RECEPTOR POSITIVE BREAST ADENOCARCINOMA NON-SMALL CELL LUNG CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC) UROTHELIAL CARCINOMA BLADDER

Contacts and locations

Locations

  • Advent Health Medical Group Radiation Oncology at Central Florida

    RECRUITING

    Orlando, Florida, 32804, United States

  • BAMF Health

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

    Contact Email: •••••@•••••

  • Biogenix Molecular, LLC

    RECRUITING

    Miami, Florida, 33165, United States

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Hoag Memorial Hospital Presbyterian

    RECRUITING

    Irvine, California, 92618, United States

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Icahn School of Medicine at Mt. Sinai

    RECRUITING

    New York, New York, 10029, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • UPMC

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • United Theranostics

    RECRUITING

    Glen Burnie, Maryland, 21061, United States

    Contact Email: •••••@•••••

  • University of Iowa

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • University of Kansas

    RECRUITING

    Westwood, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.